Page 2 - Peter Fromen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Foundations Investment Advisors LLC bought a new stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 10,688 shares of the biotechnology company’s stock, valued at approximately $154,000. A number of other hedge funds and other institutional investors have also bought and sold […]

StockNews.com upgraded shares of Pacific Biosciences of California (NASDAQ:PACB – Get Rating) to a sell rating in a report published on Tuesday morning. Several other research firms have also issued reports on PACB. Piper Sandler cut their price target on Pacific Biosciences of California from $20.00 to $13.00 in a report on Tuesday, March 1st. […]

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) fell 3.7% on Friday . The company traded as low as $10.32 and last traded at $10.53. 65,616 shares changed hands during trading, a decline of 99% from the average session volume of 4,776,942 shares. The stock had previously closed at $10.93. A number […]

Abacus Planning Group Inc. cut its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) by 13.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 155,000 shares of the biotechnology company’s stock after selling 25,000 shares during the quarter. Pacific Biosciences of California makes up 0.8% of Abacus Planning Group […]

Operator Thank you for standing by, and welcome to the Pacific Biosciences of California, Inc. fourth-quarter 2020 earnings conference call. [Operator instructions] I would now like to hand the conference over to Trevin Rard. Please go ahead. Trevin Rard -- Investor Relations Thank you. Good afternoon, and welcome to the Pacific Biosciences fourth-quarter 2020 earnings conference call. We hope that you're keeping well during this time. Earlier today, we issued a press release outlining the financial results we'll be discussing on today's call, a copy of which is available on the Investors se...